Decentralising Cell and Gene Therapy Manufacturing

Rubrik: Technik

(Treffer aus pharmind, Nr. 02, Seite 172 (2025))

Casucci E | Begarani F

Decentralising Cell and Gene Therapy Manufacturing / For Improved Patient Access · Casucci E, Begarani F · ProPharma und PBL SRL
Cell & Gene Therapy Centralised Manufacturing Decentralised Manufacturing Automated Isolators ATMPs Cell and gene therapy (CAGT) transcends traditional treatment boundaries and expands therapeutic possibilities for patients with previously limited or no viable options. Yet, the current centralised approach to CAGT manufacturing comes with significant delays, determining the effectiveness and accessibility of various CAGT products with short shelf lives. Although restricting their treatment selection, many large pharmaceutical companies favour this centralised approach. Others, unwilling to compromise on CAGT's potential and mechanism of action, have pioneered adopting a decentralised model that supports fresh product delivery to patients at the expense of high ...